Research Peptide Categories by Research Focus | Veyvora

Longevity research peptides are short amino-acid sequences used in laboratory models to probe ageing-related pathways, including mitochondrial function, proteostasis and senescence-associated signalling, and are supplied strictly for in-vitro laboratory research use only [1]. Two of the most studied sequences in this category are MOTS-c, a 16-residue mitochondrial open-reading-frame (ORF) peptide investigated for adenosine monophosphate-activated protein kinase (AMPK)-linked metabolic signalling, and SS-31 (elamipretide), a synthetic tetrapeptide studied for its association with inner-membrane cardiolipin and bioenergetic endpoints [2]. Neither compound is an MHRA- (Medicines and Healthcare products Regulatory Agency) or EMA- (European Medicines Agency) authorised anti-ageing medicine; human lifespan or age-reversal claims remain unestablished for this product class [1].

Veyvora’s catalogue organises research peptides by research focus rather than by chemical class alone, across six domains: metabolic, growth-hormone axis, repair and recovery, longevity and cellular, aesthetics, and vitality. Each domain maps to distinct in-vitro assay contexts, receptor targets and documentation requirements. This page is a directory across those six categories, distinguishing the research role of each domain and directing laboratory researchers and prospective distributors to the appropriate catalogue section for procurement and verification purposes.

All materials described on this page are intended for laboratory and in-vitro research use only. No content here constitutes human treatment, administration or dosing advice, and no human-outcome claim is made or implied.

What Research Peptide Categories by Research Focus Covers

This directory groups Veyvora’s compound catalogue by in-vitro research domain rather than by chemical class, organising sequences under six categories — metabolic, growth-hormone axis, repair and recovery, longevity and cellular, aesthetics, and vitality — so that laboratory researchers can identify the appropriate catalogue section for their assay context. The category boundary is strictly in-vitro and laboratory research use only; no section of this directory constitutes human treatment, administration or dosing guidance.

Each domain on this page maps to distinct receptor targets, assay formats and documentation requirements. The six-category structure and the representative compounds in each are confirmed from Veyvora’s catalogue; only live-only values such as current SKU, price and stock require verification against the en-GB store at the time of procurement.

Research Areas and Catalogue Entities

Veyvora’s catalogue organises research peptides into six domains: metabolic, growth-hormone axis, repair and recovery, longevity and cellular, aesthetics, and vitality. Each maps to a separate set of receptor targets, assay formats and documentation requirements. Compound assignments below reflect verified catalogue groupings; only live-only values such as current SKU, price and stock require confirmation from the en-GB store.

Metabolic Research

Veyvora’s flagship metabolic domain contains two confirmed catalogue entities: Tirzepatide, a dual GIP/GLP-1 receptor agonist, and Retatrutide, a triple GIP/GLP-1/glucagon receptor agonist. Both are studied in incretin-receptor signalling, glucose-handling and energy-expenditure models and are supplied strictly for laboratory and in-vitro research use. The Metabolic Research Peptides category page carries the compound-specific detail; Veyvora does not stock a single-agonist GLP-1 compound.

Longevity and Cellular Research

Confirmed entities in this domain include NAD+ (nicotinamide adenine dinucleotide), MOTS-c, a 16-residue mitochondrial ORF-derived peptide studied in metabolic and AMPK-linked signalling models, and SS-31 (elamipretide), a synthetic aromatic-cationic tetrapeptide investigated for cardiolipin-associated inner-membrane bioenergetics [2]. A catalogue listing or a research-use-only label does not constitute an MHRA- or EMA-authorised anti-ageing indication [1]. Researchers requiring mechanism and evidence depth beyond this overview can consult the MOTS-c and SS-31 research explainer. Other sequences sometimes grouped under longevity by merchant catalogues, including epitalon and FOXO4-DRI, are not part of Veyvora’s longevity range and carry a narrower or thinner primary literature; they must not be treated as equivalent without sequence-specific primary sources dated 2024 or later.

Aesthetics Research

The aesthetics domain covers the copper tripeptide GHK-Cu (copper-binding glycine-histidine-lysine), the GLOW and KLOW copper-peptide blends, and the melanocortin agonist Melanotan II. Published in-vitro work on copper peptides used human dermal fibroblast endpoints including collagen I/III expression, matrix metalloproteinase (MMP) activity and scratch-wound closure [3]; much of this literature predates 2024 and should be assessed for currency before use in a current protocol. A product category does not establish efficacy in people [3]. The GLOW 70 mg Skin & Repair Pen and the Aesthetics Research Peptides category page carry the concrete catalogue examples for this domain; product-level specifications, pack size and current stock status must be confirmed from the live en-GB listing at the time of procurement.

Repair & Recovery Research

The repair and recovery domain is distinct from aesthetics: it centres on BPC-157 and TB-500, supplied together as a single combined research pen for tissue-repair, angiogenesis, actin-reorganisation and cell-migration models. The Repair & Recovery Research Peptides category page carries the compound-specific mechanism and batch documentation.

Growth-Hormone Axis Research

Growth-hormone research peptides are compounds investigated in growth-hormone-axis models, including growth-hormone-releasing hormone (GHRH)-receptor ligands such as tesamorelin and CJC-1295, ghrelin/growth-hormone secretagogue receptor 1a (GHS-R1a) secretagogues such as ipamorelin, and recombinant growth hormone (somatropin) [4]. Tesamorelin holds authorised-medicine status for specified indications in certain jurisdictions, a legal-status distinction separate from its receptor pharmacology and not a basis for human-use recommendations in a research catalogue. Specific SKUs, prices and availability for this category require operator confirmation from the live en-GB listing.

Vitality Research

The vitality domain contains a single confirmed catalogue entity, PT-141 (bremelanotide), a melanocortin agonist studied for MC4R-oriented central signalling. The Vitality Research Peptides category page carries the compound-specific detail; Melanotan II, a related melanocortin agonist, is stocked under aesthetics rather than vitality.

Compare the Research Roles

The six research categories covered in this directory differ by peptide origin, molecular target and the assay endpoints each is designed to interrogate. The table below maps each domain against those criteria using verified catalogue groupings; only live SKU, price and stock require confirmation from the en-GB store.

Research category	Representative sequences	Molecular target / mechanism	Typical in-vitro endpoints	Format / documentation status
Metabolic	Tirzepatide, Retatrutide	Incretin-receptor agonism: Tirzepatide dual GIP/GLP-1; Retatrutide triple GIP/GLP-1/glucagon [4]	Receptor activation, cAMP signalling, glucose-handling and energy-expenditure readouts	Pre-filled 3 mL solution pens; confirm live SKU, price and stock on the en-GB store
Growth-hormone axis	Tesamorelin, somatropin, CJC-1295, ipamorelin	Tesamorelin and CJC-1295: GHRH-receptor ligands; ipamorelin: ghrelin/GHS-R1a secretagogue; somatropin: recombinant GH [4]	GH pulse amplitude, IGF-1 secretion in pituitary or hypothalamic cell models	Pre-filled 3 mL solution pens; confirm live SKU, price and stock on the en-GB store
Repair & recovery	BPC-157 + TB-500 (one combined pen)	Angiogenesis, collagen synthesis and NO signalling (BPC-157); actin reorganisation and cell migration (TB-500)	Scratch-wound closure, endothelial migration, collagen deposition	Single combined pre-filled 3 mL solution pen; confirm live SKU, price and stock on the en-GB store
Longevity / cellular energy	NAD+, MOTS-c, SS-31 (elamipretide)	MOTS-c: mitochondrial ORF-derived, AMPK-linked metabolic signalling [1]; SS-31: cardiolipin on the inner mitochondrial membrane, bioenergetic readouts [2]	Mitochondrial membrane potential, oxygen consumption rate, AMPK phosphorylation	Pre-filled 3 mL solution pens; confirm live SKU, price and stock on the en-GB store
Aesthetics	GHK-Cu, GLOW, KLOW, Melanotan II	Extracellular-matrix remodelling (copper peptides) [3]; melanocortin agonism (Melanotan II)	Scratch-wound closure, collagen synthesis, MMP-1/3 activity, pigmentation readouts	GLOW 70 mg pen and related pens listed; confirm live SKU, price and stock on the en-GB store
Vitality	PT-141 (bremelanotide)	MC4R-oriented central melanocortin signalling	Receptor-expression assays, hypothalamic activation models	Pre-filled 3 mL solution pen; confirm live SKU, price and stock on the en-GB store

MOTS-c and SS-31 are not interchangeable stocks: they differ in sequence length (16 residues versus 4 residues), origin (mitochondrial open reading frame versus synthetic design) and primary assay context, so identity must be confirmed against the certificate of analysis (CoA) for the stated sequence before experimental use [1][2]. Tesamorelin and ipamorelin target different receptor classes, GHRH receptor versus GHS-R1a respectively, a distinction that determines which growth-hormone-axis model each compound is appropriate for [4]. The CJC-1295 and ipamorelin research explainer covers that mechanism in greater depth; researchers selecting growth-hormone-axis material can consult the Growth & Recovery Research Pens category catalogue for current product listings.

All compounds listed are for laboratory and in-vitro research use only. No entry in this table constitutes a recommendation for human use or implies a confirmed human outcome.

Evidence Boundaries

Mechanistic data, preclinical model data and clinical trial data are three distinct evidence classes, and a finding in one does not transfer automatically to another. MOTS-c and SS-31 (elamipretide) are characterised in mitochondrial and metabolic cell models; the mechanistic papers establishing those roles should be assessed for currency before use, and no confirmed 2024–2026 primary in-vitro corpus for either sequence was available at the time of writing [1][2].

What In-Vitro Data Does and Does Not Establish

Cell-culture endpoints, including AMPK-linked signalling for MOTS-c, cardiolipin-binding and bioenergetic readouts for SS-31, and collagen and MMP expression for skin-repair sequences, describe behaviour in a controlled model system [2][3]. Such endpoints do not establish efficacy, safety or dosing in people.

Growth-hormone research peptides are investigated in growth-hormone-axis models covering secretagogues and recombinant growth hormone; their inclusion in a research category is not a recommendation for human use [4]. Tesamorelin holds authorised-medicine status for specified indications in some jurisdictions, a legal status difference that is separate from its receptor pharmacology and does not extend to unlicensed UK advertising. The Tesamorelin research explainer covers that distinction in compound-specific detail.

High-performance liquid chromatography (HPLC) purity figures on a CoA confirm chromatographic area percentage; they do not confirm concentration, endotoxin status or biological activity. The What HPLC purity does and doesn’t prove page sets out what additional analytical data a laboratory should request before in-vitro use.

Laboratory Procurement Checks

Before committing a peptide batch to cell culture, confirm identity, purity, concentration, salt form and endotoxin status from the supplier’s documentation, not from the product listing alone. A CoA should name the analytical method and the testing laboratory; an unverified merchant PDF carries less weight than data generated under ISO/IEC 17025 accreditation. HPLC area-percentage confirms chromatographic purity but does not establish net peptide content or endotoxin load, so a separate net-content figure (amino-acid analysis or equivalent) and an endotoxin result should both be present when the material will contact cells.

What to Check on a Certificate of Analysis

Confirm each of the following before first use:

• Sequence identity, mass spectrometry match to the stated sequence, with molecular weight consistent with the declared salt form
• HPLC purity, chromatogram and method included, not just a percentage figure
• Net peptide content, a value distinct from HPLC area-%, derived from amino-acid analysis or equivalent
• Salt form, trifluoroacetic acid (TFA) versus acetate matters for cell-culture cytotoxicity; residual TFA/solvent data should be available on request
• Endotoxin result, required for any cell-culture application; the testing method should be stated
• Batch number, manufacture date and retest date, a recycled or undated CoA is grounds to reject the batch
• Testing laboratory identity, ISO/IEC 17025-accredited data outweigh an unverified in-house document

Mismatched molecular weight, absent chromatograms or missing endotoxin data each provide sufficient reason to withhold a batch from in-vitro use. Use the Verify your batch against its CoA tool before proceeding: open the certificate for your specific lot number, confirm the mass spectrum matches the declared sequence and salt form, and check that an endotoxin result is present before any cell-culture application.

Handling and Storage

Lyophilised peptides are conventionally stored cold and reconstituted material is aliquoted to limit freeze-thaw cycles; these are standard laboratory practices, not independent proof of any specific supplier’s batch performance. Reconstituted shelf-life and temperature-excursion tolerance must be read from the product-specific protocol and batch file rather than assumed from category-wide guidance. Consult storage and stability guidance for detailed handling considerations. All materials are for laboratory and in-vitro research use only.

Related Research and Comparison Pages

Researchers who have confirmed which category fits their protocol should proceed directly to the relevant catalogue or comparison resource.

• Longevity & Cellular Research, the dedicated catalogue page listing current longevity-focused compounds, including mitochondrial-derived and mitochondria-targeting sequences; check here for batch availability and linked certificates of analysis.
• MOTS-c vs SS-31 comparison, resolves the selection question for researchers choosing between the 16-residue mitochondrial ORF peptide MOTS-c and the synthetic tetrapeptide SS-31 (elamipretide), which differ in sequence, target class and typical assay endpoints and are not interchangeable stocks [1][2].
• Growth & Recovery Research Pens, current product listings for growth-hormone-axis compounds including CJC-1295, ipamorelin, tesamorelin and somatropin.
• Metabolic Research Peptides, the dedicated catalogue page for the dual agonist Tirzepatide and the triple agonist Retatrutide.
• Repair & Recovery Research Peptides, the catalogue page for the combined BPC-157 + TB-500 research pen, distinct from the aesthetics range.
• Aesthetics Research Peptides, the catalogue page for copper-peptide materials (GHK-Cu, GLOW, KLOW) and the melanocortin agonist Melanotan II.
• Vitality Research Peptides, the catalogue page for PT-141 (bremelanotide).
• GLOW 70 mg Skin & Repair Pen, the catalogue entry for copper-peptide research material; confirm identity, concentration and current stock from the live en-GB listing before ordering.

A catalogue page is not a substitute for a batch-specific document.

Sources

[1] pubmed.ncbi.nlm.nih.gov, eurekalert.org, https://www.eurekalert.org/news-releases/1127364 [2] pubmed.ncbi.nlm.nih.gov, pubmed.ncbi.nlm.nih.gov, https://pubmed.ncbi.nlm.nih.gov/36532122/ [3] pubmed.ncbi.nlm.nih.gov, pubmed.ncbi.nlm.nih.gov, https://pubmed.ncbi.nlm.nih.gov/22437809/ [4] pubmed.ncbi.nlm.nih.gov, pubmed.ncbi.nlm.nih.gov, https://pubmed.ncbi.nlm.nih.gov/8296394/